Related references
Note: Only part of the references are listed.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Jennifer A. Dumont et al.
BLOOD (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
Henrik Ostergaard et al.
BLOOD (2011)
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier et al.
BLOOD (2011)
Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE
Christina Monetti et al.
ELECTROPHORESIS (2011)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Baisong Mei et al.
BLOOD (2010)
Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance
V. Terraube et al.
HAEMOPHILIA (2010)
Factor VIII and von Willebrand factor - too sweet for their own good
P. J. Lenting et al.
HAEMOPHILIA (2010)
Factor VIII-von Willebrand Factor Binding Defects in Autosomal Recessive von Willebrand Disease Type Normandy and in Mild Hemophilia A New Insights into Factor VIII-von Willebrand Factor Interactions
Marc Jacquemin
ACTA HAEMATOLOGICA (2009)
Clearance mechanisms of von Willebrand factor and factor VIII
P. J. Lenting et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Generation and characterization of a monoclonal IgG antibody to polyethylene glycol
David A. Wunderlich et al.
HYBRIDOMA (2007)
Regulated release of VWF and FVIII and the biologic implications
SL Haberichter et al.
PEDIATRIC BLOOD & CANCER (2006)
Versatile expression system for rapid and stable production of recombinant proteins
MS Cho et al.
BIOTECHNOLOGY PROGRESS (2003)
Share Paper
